Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Serum and Urinary C-terminal Agrin Fragment-22 (CAF22) as Novel Renal Function Marker in Kidney Transplant Recipients - A Prospective Observational Study

NCT02346968 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.

NCT NCT02346968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02346968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Serum and Urinary C-terminal Agrin Fragment-22 (CAF22) as Novel Renal Function Marker in Kidney Transplant Recipients - A Prospective Observational Study
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Observational
Overall status
Completed
Start date
October 8, 2014
Completion date
September 27, 2018
Enrollment
99 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

delayed graft function, kidney transplantation